Results 201 to 210 of about 872,006 (287)

Acute toxicity of ADB‐CHMINACA ‐ a case series of patients with pronounced central nervous symptoms including the posterior reversible encephalopathic syndrome

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim This report presents a series of 16 patients who were admitted to the emergency department following confirmed intake of the potent synthetic cannabinoid ADB‐CHMINACA. Methods The cases are drawn from a prospective observational study following the recreational use of synthetic cannabinoids.
Maren Hermanns‐Clausen   +7 more
wiley   +1 more source

Alcohol withdrawal in patients with liver disease. [PDF]

open access: yesFront Psychiatry
Isazade V   +5 more
europepmc   +1 more source

Repeated intradermal lipopolysaccharide challenge responses in healthy volunteers: Implications for clinical pharmacology studies

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim Intradermal application of lipopolysaccharide (LPS), a Toll‐like receptor 4 agonist, induces a local inflammatory response and is used as a human challenge model to evaluate the pharmacodynamics of investigational medicinal products. While currently applied in a single, parallel‐group setting, alternative within‐subject designs involving repeated ...
Alexandra A. J. Sillé   +12 more
wiley   +1 more source

Development of a nalmefene formulation suitable for a community‐use auto‐injector

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim Time to onset of reversal is critical when treating opioid‐induced respiratory depression and hypoxia. This study aimed to develop a formulation of the opioid antagonist nalmefene with an increased absorption rate and reduced time to onset of reversal following intramuscular administration. Methods Several absorption enhancers were screened in rats,
Alessandra Cipriano   +6 more
wiley   +1 more source

Assessment of the Treatment for Alcohol Withdrawal Syndrome With and Without Dexmedetomidine: A Retrospective Cohort Study. [PDF]

open access: yesJ Clin Med Res
Ashok A   +13 more
europepmc   +1 more source

Efficacy and safety of cannabinoids in the treatment of spasticity in multiple sclerosis: A systematic review of randomized clinical trials

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This work aimed to evaluate the efficacy and safety of cannabinoids for the treatment of MS‐related spasticity. Methods Systematic searches were conducted in PubMed, EMBASE, and LILACS on 2 December 2025. Randomized controlled trials evaluating natural or synthetic cannabinoids for MS‐related spasticity were included.
Letícia Hamm‐Buiar   +3 more
wiley   +1 more source

Paediatric clonidine medication errors: Findings from a multicentre French study

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to describe the characteristics of medication errors involving clonidine in paediatric patients and reported to French Network of Pharmacovigilance and Poison Control Centres. Methods This retrospective observational study analysed clonidine‐related medication errors reported between 1985 and June 2024 in patients under 12 years ...
Eve‐Marie Thillard   +8 more
wiley   +1 more source

Benzodiazepines use in primary care England: Prescribing patterns and adverse consequences

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Benzodiazepines (BZDs) are commonly prescribed for anxiety and insomnia but carry risks such as dependence, adverse drug reactions (ADRs) and mortality. Despite deprescribing efforts, the influence of recent prescribing trends, COVID‐19 and adverse outcomes on prescribing patterns in England remains uncertain.
Alvina Chaudhry   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy